Blomström-Lundqvist C, et al. - In patients with atrial fibrillation, researchers evaluated the quality of life (QoL) with catheter ablation vs antiarrhythmic medication at 12 months. Of the 155 patients who were randomized, 97% completed the trial. Findings revealed that the 12-month improvement in the QoL for those treated with catheter ablation vs antiarrhythmic drugs was 11.9 vs 3.1 points, respectively, on the 36-Item Short-Form Health Survey questionnaire—a difference that was statistically and clinically significant. Overall, the investigators concluded that 12-month improvement in the QoL for those treated with catheter ablation was greater vs antiarrhythmic medication in this population, despite the use of antiarrhythmic medication. Although the study may be limited by the absence of blinding, the authors maintained that catheter ablation can offer a QoL advantage. The most common adverse event in the ablation group was urosepsis and, in the medication group, atrial tachycardia.